EUVIMEDEUVIMED entdecken
Crossref

The recombinant immunodominant regions 179-344 and 550-670 from SARS-COV2 spike protein can efficiently react with patients' sera

Sama Lotfian, Akbar Soleimani, Amir Hossein Taromchi, Faezeh Sabzehei, Hossein Dinmohammadi, Keivan Nedaei

Microbial Pathogenesis · 2025

DOI: 10.1016/j.micpath.2025.107604 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbial Pathogenesis, 2025. Verfasst von Sama Lotfian und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biotechnology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, SARS-CoV-2, COVID-19, Antibodies, Viral. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Zanjan University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spike Glycoprotein, CoronavirusSARS-CoV-2COVID-19Antibodies, ViralImmunodominant EpitopesHumansRecombinant ProteinsEpitopes, B-LymphocyteFemaleMaleAdultMiddle AgedEscherichia coli

Stichwörter der Autor:innen

B-cell epitopesCOVID19ImmunoassaySARS-CoV2Spike protein

Substanzen

Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Antibodies, ViralImmunodominant EpitopesRecombinant ProteinsEpitopes, B-Lymphocyte

Autor:innen und Institutionen

  • Department of Medical Biotechnology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
  • Department of Medical Genetics and Molecular Medicine, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
  • Cancer Gene Therapy Research Center, Zanjan University of Medical Sciences, Zanjan, Iran; Department of Medical Biotechnology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran. Electronic address:…

Förderung

  • Zanjan University of Medical Sciences

Zitieren

APA

Lotfian, S., Soleimani, A., Taromchi, A. H., Sabzehei, F., Dinmohammadi, H., & Nedaei, K. (2025). The recombinant immunodominant regions 179-344 and 550-670 from SARS-COV2 spike protein can efficiently react with patients' sera. Microbial Pathogenesis. https://doi.org/10.1016/j.micpath.2025.107604

Vancouver

Lotfian S, Soleimani A, Taromchi AH, Sabzehei F, Dinmohammadi H, Nedaei K. The recombinant immunodominant regions 179-344 and 550-670 from SARS-COV2 spike protein can efficiently react with patients' sera. Microbial Pathogenesis. 2025. doi:10.1016/j.micpath.2025.107604

BibTeX
@article{Lotfian2025,
  author = {Lotfian, Sama and Soleimani, Akbar and Taromchi, Amir Hossein and Sabzehei, Faezeh and Dinmohammadi, Hossein and Nedaei, Keivan},
  title = {The recombinant immunodominant regions 179-344 and 550-670 from SARS-COV2 spike protein can efficiently react with patients' sera},
  journal = {Microbial Pathogenesis},
  year = {2025},
  doi = {10.1016/j.micpath.2025.107604}
}
Kostenlos starten →